What are the top priorities for life sciences CFOs in 2024?
Download the 2024 Life Sciences CFO Outlook Survey to find out:
How increased investor expectations are causing a shift in funding strategies.
The top drug and device research areas in 2024.
How life sciences leaders are contending with slower M&A activity.
Are you keeping pace with the competition?
In 2024, life sciences leaders can expect heightened investor expectations and fewer deals amidst economic uncertainty. Many are taking this time to strengthen fundamentals and prioritize their pipeline.
BDO’s annual survey of life sciences CFOs revealed how life sciences leaders plan to navigate opportunities and obstacles in the year ahead. The 2024 Life Sciences CFO Outlook Survey provides a glimpse into what your competitors are anticipating for the upcoming year.
See how your plans for 2024 align with critical industry data— download our report.
